Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any primary ciliary dyskinesia in which the cause of the disease is a mutation in the DNAAF3 gene.
Features include sometimes findings: Hearing loss (hearing impairment). 13 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Lungs and breathing | 3 | Respiratory distress, Bronchiectasis, Recurrent respiratory infections |
Ears |
DNAAF3 encodes dynein axonemal assembly factor 3 (541 aa). Required for the assembly of axonemal inner and outer dynein arms. Involved in preassembly of dyneins into complexes before their transport into cilia Highest expression in Testis (90.4 TPM) and Fallopian Tube (3.5 TPM).
Primary ciliary dyskinesia 2 is caused by mutations in the DNAAF3 gene on chromosome 19.
DNAAF3 is classified as a druggable target with score 0.0.
Genetic testing for DNAAF3 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for primary ciliary dyskinesia 2 has been reported in the published literature.
No clinical trials have been registered for primary ciliary dyskinesia 2.
258 publications have been identified in PubMed for primary ciliary dyskinesia 2. Kisho has analyzed 103 by research type. Research spans Epidemiology / Natural History (31%), Case Report / Case Series (16%), and Review / Meta-Analysis (15%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 32 | 31% |
Data assembled from 6 of 12 sources · Last updated Nov 2, 2026, 8:18 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
2 |
Hearing loss (hearing impairment), Otitis media |
Brain and nerves | 1 | Ciliary dyskinesia |
Hormones | 1 | Infertility |
Blood and immune system | 1 | Recurrent respiratory infections |
Patient case studies |
16 |
16% |
Research summaries | 15 | 15% |
Testing and diagnosis research | 13 | 13% |
Laboratory research | 12 | 12% |
Clinical study results | 10 | 10% |
Other research | 4 | 4% |
New treatment approaches | 1 | 1% |
Peng ZT (2026). [PMID: 41669807](https://pubmed.ncbi.nlm.nih.gov/41669807/). *Yi Chuan*. [Review / Meta-Analysis]
Kumar M (2026). [PMID: 42112810](https://pubmed.ncbi.nlm.nih.gov/42112810/). *Pediatr Pulmonol*. [Diagnostic / Biomarker]
Özay M (2026). [PMID: 41589461](https://pubmed.ncbi.nlm.nih.gov/41589461/). *Turk J Haematol*. [Case Report / Case Series]
AbdulWahab A (2026). [PMID: 41267578](https://pubmed.ncbi.nlm.nih.gov/41267578/). *Clin Genet*. [Epidemiology / Natural History]
Nussstein H (2026). [PMID: 40967762](https://pubmed.ncbi.nlm.nih.gov/40967762/). *Eur Respir J*. [Epidemiology / Natural History]
Khalaili L (2026). [PMID: 40610053](https://pubmed.ncbi.nlm.nih.gov/40610053/). *Eur Respir J*. [Epidemiology / Natural History]
Harman K (2026). [PMID: 41889169](https://pubmed.ncbi.nlm.nih.gov/41889169/). *Pediatr Pulmonol*. [Review / Meta-Analysis]
Vermaut A (2026). [PMID: 41412720](https://pubmed.ncbi.nlm.nih.gov/41412720/). *Eur Respir J*. [Other]
Batu U (2026). [PMID: 41837195](https://pubmed.ncbi.nlm.nih.gov/41837195/). *Front Pediatr*. [Clinical Trial Publication]
Bertini V (2026). [PMID: 42061474](https://pubmed.ncbi.nlm.nih.gov/42061474/). *Respir Med*. [Diagnostic / Biomarker]
AI-curated news mentioning primary ciliary dyskinesia 2
Updated Sep 28, 2026
A systematic review highlights the potential of artificial intelligence and digital tools in the screening, diagnosis, and characterization of primary ciliary dyskinesia. This research could enhance diagnostic accuracy and patient management for this rare condition.
ReCode Therapeutics appoints a new CEO to lead its efforts in advancing clinical programs for cystic fibrosis and primary ciliary dyskinesia. This leadership change follows the company's recent clinical validation earlier this year.
A recent case series from the SV-ONE Registry highlights the clinical characteristics of patients with Fontan circulation and primary ciliary dyskinesia. This study provides valuable insights into the intersection of these two rare conditions.
A recent study highlights the occurrence of pulmonary exacerbations in patients with primary ciliary dyskinesia, shedding light on the respiratory challenges faced by this population. Understanding these exacerbations is crucial for improving patient management and outcomes.